CVS Health Posts $2.09 EPS, Beating Estimates by 29% in Q3

CVS Health reported quarterly earnings of $2.09 per share, beating the Zacks Consensus Estimate of $1.62 by 29.01% for the quarter ended September 2026. The figure compares with adjusted earnings of $1.60 per share a year earlier, and it marks the fourth consecutive quarter in which the company has surpassed consensus EPS estimates.

Revenue tells the same story. CVS posted $108.4 billion for the quarter, surpassing the consensus estimate by 3.20% and rising from $102.87 billion in the year-ago period. The company has now topped consensus revenue estimates four times over the last four quarters.

How does this compare with the prior quarter?

The beat was the second large one in a row. A quarter ago, analysts expected the drugstore chain and pharmacy benefits manager (a company that negotiates drug prices and administers claims for insurers and employers) to post $1.87 per share. CVS delivered $2.58 instead, a surprise of +37.97%.

Taken together, the two reports show a company consistently clearing expectations by wide margins rather than scraping past them — the kind of pattern that forces analysts to rebuild their models rather than nudge them.

What do the numbers mean for practitioners?

For finance teams watching the medical services sector, the key data points are:

• Q3 EPS of $2.09 versus a $1.62 consensus; year-ago figure was $1.60.
• Q3 revenue of $108.4 billion versus $102.87 billion a year earlier, a 3.20% beat against estimates.
• Four straight quarters of EPS and revenue beats.
• Shares up about 15.2% year-to-date, against a 10.6% gain for the S&P 500.

The sustainability of the stock's immediate price movement, based on the newly released figures and future earnings expectations, will depend largely on management's commentary on the earnings call. The reported numbers set the floor; the guidance sets the ceiling.

What comes next for the estimates?

Attention now shifts to how analysts revise their models. Ahead of this release, the estimate revision trend for CVS Health was mixed — a state of affairs that translates into a Zacks Rank #3 (Hold), meaning the shares are expected to perform roughly in line with the market in the near term.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, so the days following this report matter as much as the report itself. Investors can track revisions directly or rely on rating tools built to capture them.

Current consensus expectations frame the bar CVS must clear:

• Coming quarter: EPS of $1.26 on revenue of $107.12 billion.
• Current fiscal year: EPS of $8.02 on revenue of $418.17 billion.

Whether those estimates move up after a second consecutive large beat, and what management signals on the call about medical cost trends and pharmacy margins, will determine whether the 15.2% year-to-date outperformance extends into the next quarter.